These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 18583085)

  • 1. Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia.
    Bhavnani SM; Forrest A; Hammel JP; Drusano GL; Rubino CM; Ambrose PG
    Diagn Microbiol Infect Dis; 2008 Sep; 62(1):99-101. PubMed ID: 18583085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New quinolones for the treatment of community-acquired pneumonia--contra].
    Egger M
    Dtsch Med Wochenschr; 2003 May; 128(19):1071. PubMed ID: 12736860
    [No Abstract]   [Full Text] [Related]  

  • 3. [New quinolones for the treatment of community-acquired pneumonia--pro].
    Zimmerli S
    Dtsch Med Wochenschr; 2003 May; 128(19):1070. PubMed ID: 12736859
    [No Abstract]   [Full Text] [Related]  

  • 4. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure.
    Jacobs MR
    Clin Infect Dis; 2002 Sep; 35(5):565-9. PubMed ID: 12173130
    [No Abstract]   [Full Text] [Related]  

  • 5. A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic.
    File TM; Monte SV; Schentag JJ; Paladino JA; Klugman KP; Lavin B; Yu VL; Singer ME; Adelman MH
    Int J Antimicrob Agents; 2009 Jan; 33(1):58-64. PubMed ID: 18835762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).
    Noreddin AM; Marras TK; Sanders K; Chan CK; Hoban DJ; Zhanel GG
    Int J Antimicrob Agents; 2004 Nov; 24(5):479-84. PubMed ID: 15519481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
    Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
    J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotics for childhood community-acquired pneumonia in a region with a high prevalence of penicillin non-susceptible Streptococcus pneumoniae.
    Lee WK; Young BW
    J Antimicrob Chemother; 2005 Sep; 56(3):603-5. PubMed ID: 16040621
    [No Abstract]   [Full Text] [Related]  

  • 9. Efflux of novel quinolones in contemporary Streptococcus pneumoniae isolates from community-acquired pneumonia.
    Lismond A; Carbonnelle S; Tulkens PM; Van Bambeke F
    J Antimicrob Chemother; 2011 Apr; 66(4):948-51. PubMed ID: 21393137
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of community-acquired pneumonia--treatment].
    Andersen LV; Brock B; Jakobsen P; Nielsen LP
    Ugeskr Laeger; 2008 Jan; 170(3):127-30. PubMed ID: 18208726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical solution to antimicrobial resistance in community-acquired pneumonia: narrowing the spectrum of antimicrobial therapy: comment on "Current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy".
    Yu VL
    Arch Intern Med; 2011 Jan; 171(2):172-3. PubMed ID: 21263107
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk factors and clinical outcomes of penicillin resistant S. pneumoniae community-acquired pneumonia in Khon Kaen, Thailand.
    Reechaipichitkul W; Assawasanti K; Chaimanee P
    Southeast Asian J Trop Med Public Health; 2006 Mar; 37(2):320-6. PubMed ID: 17124993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    File TM; Garau J; Jacobs MR; Wynne B; Twynholm M; Berkowitz E
    Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current use of penicillin in community-acquired pneumococcal pneumonias].
    Gaztelurrutia L; Zalacaín R; Rubio G; Hernández JL; Urra E; Hernández M; Garea C; Barrón J
    Enferm Infecc Microbiol Clin; 1994 Jan; 12(1):17-20. PubMed ID: 8155749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of tigecycline against Streptococcus pneumoniae, an important causative pathogen of community-acquired pneumonia (CAP).
    Hawser SP
    J Infect; 2010 Apr; 60(4):306-8. PubMed ID: 20144899
    [No Abstract]   [Full Text] [Related]  

  • 16. Scenario 1: a patient with mild community-acquired pneumonia--introduction to clinical trial design issues.
    Gilbert DN
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S121-2. PubMed ID: 18986276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What can we learn from the time course of untreated and partially treated community-onset Streptococcus pneumoniae pneumonia? A clinical perspective on superiority and noninferiority trial designs for mild community-acquired pneumonia.
    File TM; Schentag JJ
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S157-65. PubMed ID: 18986283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibility of pneumococcal isolates causing bacteraemic pneumococcal pneumonia: analysis using current breakpoints and fluoroquinolone pharmacodynamics.
    Feldman C; Brink AJ; von Gottberg A; Wolter N; de Gouveia L; Perovic O; Klugman KP
    Int J Antimicrob Agents; 2010 Jul; 36(1):95-7. PubMed ID: 20378315
    [No Abstract]   [Full Text] [Related]  

  • 19. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia.
    Jones RN; Jacobs MR; Sader HS
    Int J Antimicrob Agents; 2010 Sep; 36(3):197-204. PubMed ID: 20558045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial resistance and treatment of community-acquired pneumonia.
    Mandell LA
    Clin Chest Med; 2005 Mar; 26(1):57-64. PubMed ID: 15802166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.